 1.IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKINGProduct IdentifierMaterial Name:  Irinotecan Hydrochloride InjectionTrade Name:CAMPTOSAR; CAMPTOChemical Family:MixtureRelevant Identified Uses of the Substance or Mixture and Uses Advised AgainstIntended Use:Pharmaceutical product used as AntineoplasticDetails of the Supplier of the Safety Data Sheet2. HAZARDS IDENTIFICATIONClassification of the Substance or MixtureGHS - ClassificationGerm Cell Mutagenicity: Category 2Reproductive Toxicity: Category 1BLabel ElementsSignal Word:DangerHazard Statements:H341 - Suspected of causing genetic defectsH360D - May damage the unborn childPrecautionary Statements:P202 - Do not handle until all safety precautions have been read and understoodP281 - Use personal protective equipment as requiredP308 + P313 - IF exposed or concerned: Get medical attention/adviceP405 - Store locked upP501 - Dispose of contents/container in accordance with all local and national regulations_______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONPfizer LtdRamsgate RoadSandwich, KentCT13 9NJUnited Kingdom+00 44 (0)1304 616161Revision date: 10-Aug-2016Emergency telephone number:CHEMTREC (24 hours): 1-800-424-9300Emergency telephone number:International CHEMTREC (24 hours): +1-703-527-3887Version: 3.1Contact E-Mail:pfizer-MSDS@pfizer.com         SAFETY DATA SHEETPage  1 of 11Pfizer IncPfizer Pharmaceuticals Group 235 East 42nd StreetNew York, New York 100171-800-879-3477         SAFETY DATA SHEET_______________________________________________________________________________________________________Other HazardsAn Occupational Exposure Value has been established for one or more of the ingredients (seeSection 8).Note:This document has been prepared in accordance with standards for workplace safety, whichrequires the inclusion of all known hazards of the product or its ingredients regardless of thepotential risk.  The precautionary statements and warning included may not apply in all cases.Your needs may vary depending upon the potential for exposure in your workplace.3. COMPOSITION / INFORMATION ON INGREDIENTSHazardousIngredientCAS NumberEUEINECS/ELINCSListGHS Classification%Irinotecan Hydrochloride100286-90-6Not ListedAcute Tox.4 (H302)Repr.1B (H360D)Muta.2 (H341)2%Sodium hydroxide1310-73-2215-185-5Skin Corr.1A (H314)**Lactic acid50-21-5200-018-0Eye Dam. 1 (H318)Skin Irrit. 2 (H315)*Hydrogen chloride7647-01-0231-595-7STOT SE 3 (H335)Skin Corr. 1A (H314)Press. GasAcute Tox. 3 (H331)**IngredientCAS NumberEUEINECS/ELINCSListGHS Classification%Sorbitol crystalline - NF50-70-4200-061-5Not Listed*Water7732-18-5231-791-2Not Listed*Additional Information:* Proprietary** to adjust pHIngredient(s) indicated as hazardous have been assessed under standards for workplacesafety.In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture hasbeen withheld as a trade secret.For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 164. FIRST AID MEASURESDescription of First Aid MeasuresEye Contact:Flush with water while holding eyelids open for at least 15 minutes.  Seek medical attentionimmediately.Skin Contact:Remove contaminated clothing.  Flush area with large amounts of water.  Use soap.  Seekmedical attention.Ingestion:Never give anything by mouth to an unconscious person.  Wash out mouth with water.  Do notinduce vomiting unless directed by medical personnel.  Seek medical attention immediately.Inhalation:Remove to fresh air and keep patient at rest.  Seek medical attention immediately.Most Important Symptoms and Effects, Both Acute and Delayed_______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONRevision date: 10-Aug-2016Material Name:  Irinotecan Hydrochloride InjectionVersion: 3.1Page  2 of 11         SAFETY DATA SHEET_______________________________________________________________________________________________________Symptoms and Effects ofExposure:For information on potential signs and symptoms of exposure, See Section 2 - HazardsIdentification and/or Section 11 - Toxicological Information.Medical ConditionsAggravated by Exposure:None knownIndication of the Immediate Medical Attention and Special Treatment NeededNotes to Physician:None5. FIRE FIGHTING MEASURESExtinguishing Media:Extinguish fires with CO2, extinguishing powder, foam, or water.Special Hazards Arising from the Substance or MixtureHazardous CombustionProducts:Formation of toxic gases is possible during heating or fire.Fire / Explosion Hazards:Not flammable.Advice for Fire-FightersDuring all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.6. ACCIDENTAL RELEASE MEASURESPersonal Precautions, Protective Equipment and Emergency ProceduresPersonnel involved in clean-up should wear appropriate personal protective equipment (see Section 8).  Minimize exposure.Environmental PrecautionsPlace waste in an appropriately labeled, sealed container for disposal.  Care should be taken to avoid environmental release.Methods and Material for Containment and Cleaning UpMeasures for Cleaning /Collecting:Contain the source of spill if it is safe to do so.  Collect spill with absorbent material.  Clean spillarea thoroughly.Additional Consideration forLarge Spills:Non-essential personnel should be evacuated from affected area.  Report emergencysituations immediately.  Clean up operations should only be undertaken by trained personnel.7. HANDLING AND STORAGEPrecautions for Safe HandlingAvoid breathing vapor or mist.  Avoid contact with eyes, skin and clothing.  When handling, use appropriate personal protectiveequipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided.  Review andimplement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure orenvironmental releases.  Potential points of process emissions of this material to the atmosphere should be controlled with dustcollectors, HEPA filtration systems or other equivalent controls.Conditions for Safe Storage, Including any IncompatibilitiesStorage Conditions:Store as directed by product packaging.Specific end use(s):Pharmaceutical product used as Antineoplastic8. EXPOSURE CONTROLS / PERSONAL PROTECTIONControl ParametersRefer to available public information for specific member state Occupational Exposure Limits._______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONPage  3 of 11Pfizer OEL TWA-8 Hr:2 µg/m3Revision date: 10-Aug-2016Material Name:  Irinotecan Hydrochloride InjectionVersion: 3.1Irinotecan Hydrochloride         SAFETY DATA SHEET_______________________________________________________________________________________________________8. EXPOSURE CONTROLS / PERSONAL PROTECTION_______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONPoland OEL - TWA0.5 mg/m3Version: 3.1Page  4 of 11Slovakia OEL - TWA2 mg/m3Bulgaria OEL - TWASlovenia OEL - TWA2 mg/m32.0 mg/m3Sweden OEL - TWAs1 mg/m3Sodium hydroxideSwitzerland OEL -TWAs2 mg/m3Czech Republic OEL - TWA1 mg/m3Hydrogen chlorideACGIH Ceiling Threshold Limit:2 ppmAustralia PEAK5 ppm7.5 mg/m3Estonia OEL - TWA1 mg/m3Austria OEL - MAKs5 ppm8 mg/m3ACGIH Ceiling Threshold Limit:Belgium OEL - TWA5 ppm8 mg/m3France OEL - TWABulgaria OEL - TWA5 ppm8.0 mg/m32 mg/m32 mg/m3Cyprus OEL - TWA5 ppm8 mg/m3Czech Republic OEL - TWA8 mg/m3Greece OEL - TWA2 mg/m3Estonia OEL - TWA5 ppm8 mg/m3Revision date: 10-Aug-2016Germany - TRGS 900 - TWAs2 ppm3 mg/m3Germany (DFG) - MAK2 ppm3.0 mg/m3Hungary OEL - TWA2 mg/m3Greece OEL - TWA5 ppm7 mg/m3Australia PEAK2 mg/m3Hungary OEL - TWA8 mg/m3Japan - OELs - CeilingsIreland OEL - TWAs5 ppm8 mg/m32 mg/m3Italy OEL - TWA5 ppm8 mg/m3Material Name:  Irinotecan Hydrochloride InjectionJapan - OELs - Ceilings2 ppm3.0 mg/m3Latvia OEL - TWA0.5 mg/m3Latvia OEL - TWA5 ppm8 mg/m3Lithuania OEL - TWA5 ppm8 mg/m3OSHA - Final PELS - TWAs:2 mg/m3Austria OEL - MAKs2 mg/m3         SAFETY DATA SHEET_______________________________________________________________________________________________________8. EXPOSURE CONTROLS / PERSONAL PROTECTIONAnalytical Method:Analytical method available for Irinotecan hydrochloride.  Contact Pfizer Inc for furtherinformation.Exposure ControlsEngineering Controls:Engineering controls should be used as the primary means to control exposures.  Generalroom ventilation is adequate unless the process generates dust, mist or fumes.  Keep airbornecontamination levels below the exposure limits listed above in this section.Personal ProtectiveEquipment:Refer to applicable national standards and regulations in the selection and use of personalprotective equipment (PPE).  Contact your safety and health professional or safety equipmentsupplier for assistance in selecting the correct protective clothing/equipment based on anassessment of the workplace conditions, other chemicals used or present in the workplace andspecific operational processes.Hands:Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drugproduct is possible and for bulk processing operations.  (Protective gloves must meet thestandards in accordance with EN374, ASTM F1001 or international equivalent.)Eyes:Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet thestandards in accordance with EN166, ANSI Z87.1 or international equivalent.)Skin:Impervious disposable protective clothing is recommended if skin contact with drug product ispossible and for bulk processing operations.  (Protective clothing must meet the standards inaccordance with EN13982, ANSI 103 or international equivalent.)Respiratory protection:Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) isexceeded, wear an appropriate respirator with a protection factor sufficient to control exposuresto below the OEL (e.g. particulate respirator with a full mask, P3 filter).  (Respirators must meetthe standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)9. PHYSICAL AND CHEMICAL PROPERTIESSolvent Solubility:No data availableWater Solubility:No data availableSolubility:Soluble: Water_______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTION5 ppm8 mg/m3Slovakia OEL - TWA5 ppm8.0 mg/m3Slovenia OEL - TWA5 ppm8 mg/m3Malta OEL - TWA5 ppm8 mg/m3Spain OEL - TWA5 ppm7.6 mg/m3Revision date: 10-Aug-2016Physical State:Aqueous solutionSwitzerland OEL -TWAs2 ppm3.0 mg/m3Color:Pale yellowOdor:No data available.Odor Threshold:No data available.Molecular Formula:MixtureVietnam OEL - TWAs5 mg/m3Molecular Weight:MixtureNetherlands OEL - TWA8 mg/m3Material Name:  Irinotecan Hydrochloride InjectionPoland OEL - TWA5 mg/m3Version: 3.1Page  5 of 11Portugal OEL - TWA5 ppm8 mg/m3Luxembourg OEL - TWARomania OEL - TWA5 ppm8 mg/m3         SAFETY DATA SHEET_______________________________________________________________________________________________________9. PHYSICAL AND CHEMICAL PROPERTIESpH:3.5Melting/Freezing Point (°C):No data availableBoiling Point (°C):No data available.Partition Coefficient: (Method, pH, Endpoint, Value)Decomposition Temperature (°C):No data available.Evaporation Rate (Gram/s):No data availableVapor Pressure (kPa):No data availableVapor Density (g/ml):No data availableRelative Density:No data availableViscosity:No data availableFlammablity:Autoignition Temperature (Solid) (°C):No data availableFlammability (Solids):No data availableFlash Point (Liquid) (°C):No data availableUpper Explosive Limits (Liquid) (% by Vol.):No data availableLower Explosive Limits (Liquid) (% by Vol.):No data available10. STABILITY AND REACTIVITYReactivity:No data availableChemical Stability:Stable under normal conditions of use.Possibility of Hazardous ReactionsOxidizing Properties:No data availableConditions to Avoid:Fine particles (such as dust and mists) may fuel fires/explosions.Incompatible Materials:As a precautionary measure, keep away from strong oxidizersHazardous DecompositionProducts:No data available11. TOXICOLOGICAL INFORMATIONInformation on Toxicological EffectsGeneral Information:The information included in this section describes the potential hazards of the individualingredients.Short Term:May be harmful if swallowed. (based on components) .Long Term:Repeat-dose studies in animals have shown a potential to cause adverse effects ongastrointestinal system. Animal studies have shown a potential to cause adverse effects on thefetus.Known Clinical Effects:Effects reported during clinical use included vomiting and diarrhea.  Effects on blood andblood-forming organs have also occurred.  Serious allergic reactions, including anaphylaxis,have been reported._______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONNo data availableNo data availableWaterIrinotecan HydrochlorideNo data availableRevision date: 10-Aug-2016Sodium hydroxideMeasured     N/A     Log P     4.37No data availableMaterial Name:  Irinotecan Hydrochloride InjectionHydrogen chlorideLactic acidNo data availableVersion: 3.1Page  6 of 11Sorbitol crystalline - NF         SAFETY DATA SHEET_______________________________________________________________________________________________________11. TOXICOLOGICAL INFORMATIONAcute Toxicity: (Species, Route, End Point, Dose)Acute Toxicity Comments:A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievableat the highest dose used in the test.Irritation / Sensitization: (Study Type, Species, Severity)Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))_______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONEye Irritation     Rabbit     MinimalMouse      IP      LD50   40   mg/kgSkin Irritation     Rabbit     No effectPage  7 of 11Antigenicity- Passive cutaneous anaphylaxis     Mouse     NegativeHydrogen chlorideLactic acidRat     Oral     LD 50       1026mg/kgEye Irritation     Rabbit     SevereRat      Sub-tenon injection (eye)     LC50 1H   3,124  ppmSkin Irritation     Rabbit     Moderate SevereSodium hydroxideMouse      Inhalation     LC50 1H   1,108ppmEye Irritation     Rabbit     SevereLactic acidSkin Irritation     Rabbit     SevereMouse     Oral     LD50   900mg/kgRevision date: 10-Aug-2016Material Name:  Irinotecan Hydrochloride InjectionIrinotecan HydrochlorideSorbitol crystalline - NF4 Week(s)      Rat      Oral      10  mg/kg/day      LOAEL      Bone marrow, Gastrointestinal SystemRat      Oral      LD50   3543  mg/kg6 Month(s)      Rat      Intravenous        0.016  mg/kg/day      NOAEL      Blood, Bone Marrow, Male reproductive systemMouse     Oral     LD50   17,800  mg/kg4 Week(s)      Dog      Oral        1  mg/kg/day      NOAEL      Bone Marrow, Gastrointestinal systemIrinotecan Hydrochloride26 Week(s)      Dog      Intravenous        0.01  mg/kg/day      NOAEL      BloodRat     Para-periosteal     LD50   7100mg/kgRabbit     Dermal      LD50      >  2000 mg/kgVersion: 3.1Sodium hydroxideIrinotecan HydrochlorideRat     Oral     LD 50       867  mg/kg         SAFETY DATA SHEET_______________________________________________________________________________________________________11. TOXICOLOGICAL INFORMATIONGenetic Toxicity: (Study Type, Cell Type/Organism, Result)Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))Carcinogen Status:None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.12. ECOLOGICAL INFORMATIONEnvironmental Overview:The environmental characteristics of this material have not been fully evaluated.  Releases tothe environment should be avoided.Toxicity:No data availablePersistence and Degradability:No data availableBio-accumulative Potential:Partition Coefficient: (Method, pH, Endpoint, Value)Mobility in Soil:No data available_______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONBacterial Mutagenicity (Ames)      Salmonella       NegativePrenatal & Postnatal Development      Rat      Intravenous        6  mg/kg/day      LOAEL      Neonatal toxicityIn Vitro Cytogenetics      Chinese Hamster Ovary (CHO) cells      PositiveVersion: 3.1Page  8 of 11In Vivo Micronucleus      Mouse      PositiveEmbryo / Fetal Development      Rat      Intravenous        0.24  mg/kg/day      NOAEL      TeratogenicIrinotecan HydrochlorideIrinotecan HydrochlorideEmbryo / Fetal Development      Rabbit      Intravenous        0.06  mg/kg/day      NOAEL      Teratogenic104 Week(s)     Rat     Intravenous  2  mg/kg/week     NOAEL     Not carcinogenicIrinotecan HydrochlorideLactic acidMeasured     N/A     Log P     4.37Embryo / Fetal Development      Rat      Intravenous      6  mg/kg/day      NOAEL      FetotoxicityReproductive & Fertility      Rat      Oral      6.25  mg/kg/day      NOEL      Fertility, Not teratogenicHydrogen chlorideRevision date: 10-Aug-2016IARC:Group 3 (Not Classifiable)Embryo / Fetal Development      Rabbit      Intravenous        6  mg/kg/day      NOAEL      FetotoxicityIrinotecan HydrochlorideMaterial Name:  Irinotecan Hydrochloride Injection         SAFETY DATA SHEET_______________________________________________________________________________________________________13. DISPOSAL CONSIDERATIONSWaste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations.  Member Statespecific and Community specific provisions must be considered.  Considering the relevantknown environmental and human health hazards of the material, review and implementappropriate technical and procedural waste water and waste disposal measures to preventoccupational exposure and environmental release.  It is recommended that waste minimizationbe practiced.  The best available technology should  be utilized to prevent environmentalreleases. This may include destructive techniques for waste and wastewater.14. TRANSPORT INFORMATIONThe following refers to all modes of transportation unless specified below.Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.15. REGULATORY INFORMATIONSafety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture_______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONInventory - United States TSCA - Sect. 8(b)PresentNot ListedAustralia (AICS):PresentVersion: 3.1REACH - Annex IV - Exemptions from theobligations of Register:PresentCalifornia Proposition 65Not ListedEU EINECS/ELINCS List200-061-5Page  9 of 11Sodium hydroxideCERCLA/SARA 313 Emission reportingNot ListedEU EINECS/ELINCS ListNot ListedCERCLA/SARA Hazardous Substancesand their Reportable Quantities:1000 lb454 kgRevision date: 10-Aug-2016California Proposition 65Not ListedSorbitol crystalline - NFInventory - United States TSCA - Sect. 8(b)PresentIrinotecan HydrochlorideAustralia (AICS):PresentCERCLA/SARA 313 Emission reportingStandard for the Uniform Schedulingfor Drugs and Poisons:Schedule 5Schedule 6Not ListedEU EINECS/ELINCS List215-185-5Material Name:  Irinotecan Hydrochloride InjectionCalifornia Proposition 65Not ListedCERCLA/SARA 313 Emission reporting         SAFETY DATA SHEET_______________________________________________________________________________________________________15. REGULATORY INFORMATION16. OTHER INFORMATIONText of CLP/GHS Classification abbreviations mentioned in Section 3Acute toxicity, oral-Cat.4; H302 - Harmful if swallowedAcute toxicity, inhalation-Cat.3; H331 - Toxic if inhaledSkin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damageSerious eye damage/eye irritation-Cat.1; H318 - Causes serious eye damageSkin corrosion/irritation-Cat.2;  H315 - Causes skin irritationSpecific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritationData Sources:Pfizer proprietary drug development information. Publicly available toxicity information.Reasons for Revision:Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. UpdatedSection 8 - Exposure Controls / Personal Protection.Revision date:10-Aug-2016Prepared by:Product Stewardship Hazard CommunicationPfizer Global Environment, Health, and Safety Operations_______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONPage 10 of 11CERCLA/SARA 313 Emission reporting1.0 %Australia (AICS):CERCLA/SARA Hazardous Substancesand their Reportable Quantities:5000 lb2270 kgPresentCERCLA/SARA - Section 302 Extremely HazardousTPQs500 lbLactic acidCERCLA/SARA - Section 302 Extremely HazardousSubstances EPCRA RQs5000 lbEU EINECS/ELINCS List200-018-0California Proposition 65Not ListedInventory - United States TSCA - Sect. 8(b)PresentWaterAustralia (AICS):PresentStandard for the Uniform Schedulingfor Drugs and Poisons:Schedule 5Schedule 6CERCLA/SARA 313 Emission reportingEU EINECS/ELINCS List231-595-7CERCLA/SARA 313 Emission reportingNot ListedNot ListedCalifornia Proposition 65Not ListedRevision date: 10-Aug-2016Inventory - United States TSCA - Sect. 8(b)PresentCalifornia Proposition 65Not ListedAustralia (AICS):PresentMaterial Name:  Irinotecan Hydrochloride InjectionREACH - Annex IV - Exemptions from theobligations of Register:PresentEU EINECS/ELINCS List231-791-2Inventory - United States TSCA - Sect. 8(b)PresentHydrogen chlorideVersion: 3.1         SAFETY DATA SHEET_______________________________________________________________________________________________________Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, itis without warranty of any kind, expressed or implied.  If data for a hazard are not included in this document there is no knowninformation at this time.End of Safety Data Sheet_______________________________________________________________________________________________________IRINOTECAN HYDROCHLORIDE INJECTIONMaterial Name:  Irinotecan Hydrochloride InjectionVersion: 3.1Page 11 of 11Revision date: 10-Aug-2016